Literature DB >> 19041189

Low-dose naltrexone for disease prevention and quality of life.

Norman Brown1, Jaak Panksepp.   

Abstract

The use of low-dose naltrexone (LDN) for the treatment and prophylaxis of various bodily disorders is discussed. Accumulating evidence suggests that LDN can promote health supporting immune-modulation which may reduce various oncogenic and inflammatory autoimmune processes. Since LDN can upregulate endogenous opioid activity, it may also have a role in promoting stress resilience, exercise, social bonding, and emotional well-being, as well as amelioration of psychiatric problems such a autism and depression. It is proposed that LDN can be used effectively as a buffer for a large variety of bodily and mental ailments through its ability to beneficially modulate both the immune system and the brain neurochemistries that regulate positive affect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19041189     DOI: 10.1016/j.mehy.2008.06.048

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  24 in total

1.  Combination of Levo-Tetrahydropalmatine and Low Dose Naltrexone: A Promising Treatment for Prevention of Cocaine Relapse.

Authors:  Sarah Sushchyk; Zheng-Xiong Xi; Jia Bei Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-02-22       Impact factor: 4.030

2.  Recalcitrant Hailey-Hailey Disease Successfully Treated with Low-dose Naltrexone.

Authors:  McBride Michael; Witkoff Benjamin M; Trotter Shannon C
Journal:  J Clin Aesthet Dermatol       Date:  2020-11-01

Review 3.  μ opioid receptor, social behaviour and autism spectrum disorder: reward matters.

Authors:  Lucie P Pellissier; Jorge Gandía; Thibaut Laboute; Jérôme A J Becker; Julie Le Merrer
Journal:  Br J Pharmacol       Date:  2017-05-04       Impact factor: 8.739

Review 4.  Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures.

Authors:  Karina Liubchenko; Kevin Kordbacheh; Nika Khajehdehi; Tanja Visnjevac; Frederick Ma; James S Khan; Myles Storey; Alaa Abd-Elsayed; Ognjen Visnjevac
Journal:  Adv Ther       Date:  2020-12-18       Impact factor: 3.845

5.  Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.

Authors:  Lisa M Fucito; Aesoon Park; Suzy Bird Gulliver; Margaret E Mattson; Ralitza V Gueorguieva; Stephanie S O'Malley
Journal:  Biol Psychiatry       Date:  2012-04-26       Impact factor: 13.382

6.  Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.

Authors:  Katherine B Peters; Mary L Affronti; Sarah Woodring; Eric Lipp; Patrick Healy; James E Herndon; Elizabeth S Miller; Maria W Freeman; Dina M Randazzo; Annick Desjardins; Henry S Friedman
Journal:  Support Care Cancer       Date:  2022-01-10       Impact factor: 3.603

Review 7.  Vulvar Hailey-Hailey disease treated with low-dose naltrexone: case report and literature review.

Authors:  Marina Sousa Gomes; Joana Araújo Pereira; Vera Trocado; João Pedro Prata; Vera Teixeira; Paula Pinheiro
Journal:  Arch Gynecol Obstet       Date:  2020-08-10       Impact factor: 2.344

8.  Low-Dose Naltrexone Treatment of Familial Benign Pemphigus (Hailey-Hailey Disease).

Authors:  Omer Ibrahim; Sara R Hogan; Alok Vij; Anthony P Fernandez
Journal:  JAMA Dermatol       Date:  2017-10-01       Impact factor: 10.282

9.  Effect of Naltrexone Hydrochloride on Cytochrome P450 1A2, 2C9, 2D6, and 3A4 Activity in Human Liver Microsomes.

Authors:  Haitham AlRabiah; Abdul Ahad; Gamal A E Mostafa; Fahad I Al-Jenoobi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

10.  Pilot study of tolerability and safety of opioid receptor antagonists as novel therapies for chronic pain among persons living with HIV with past year heavy drinking: a randomized controlled trial.

Authors:  Sally Bendiks; Debbie M Cheng; Elena Blokhina; Marina Vetrova; Elena Verbitskaya; Natalia Gnatienko; Kendall Bryant; Evgeny Krupitsky; Jeffrey H Samet; Judith I Tsui
Journal:  AIDS Care       Date:  2021-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.